What clinical trials studied Erleada (apalutamide) combination regimens?
Erleada (apalutamide) has been studied in multiple combination approaches, most prominently in advanced prostate cancer settings where it is paired with other standard therapies such as androgen deprivation therapy (ADT). In these studies, the goal is usually to deepen androgen suppression and improve survival outcomes compared with ADT alone.
Which trial results are most often cited for apalutamide combinations?
The most cited apalutamide combination evidence comes from phase 3 programs in non-metastatic castration-resistant prostate cancer (nmCRPC), where apalutamide is used in combination with ADT (to maintain castrate androgen levels). These trials are the basis for Erleada’s clinical use and guideline adoption in that disease setting.
Are there apalutamide combination trials in metastatic castration-resistant prostate cancer (mCRPC)?
Yes. Apalutamide has also been evaluated with combination strategies in metastatic disease, including regimens where the study design uses continued androgen-axis suppression as the backbone and adds apalutamide to intensify treatment. The exact study endpoints and eligibility criteria vary by trial (for example, time from progression, metastatic status, prior therapies, and use of imaging).
What about apalutamide combinations in metastatic castration-sensitive prostate cancer (mCSPC)?
Apalutamide has clinical-trial evaluation in earlier-stage advanced disease as well, including metastatic hormone-sensitive (castration-sensitive) prostate cancer. In those studies, the combination concept is typically built around ADT plus apalutamide, with primary endpoints often focusing on radiographic progression and survival.
What outcomes do apalutamide combination trials usually measure?
Across combination trials, the main measured endpoints generally include radiographic progression-free survival (rPFS), overall survival (OS), and time to symptomatic progression. Safety outcomes focus on adverse events related to androgen-axis therapy and those specific to apalutamide, including risks that have shown up across studies (for example, falls or fractures in some populations, fatigue, rash, and lab changes).
Where can I find apalutamide patent and development context tied to these trials?
DrugPatentWatch.com tracks patent and exclusivity status and often links to broader development history that can help contextualize trial programs and commercial follow-on efforts. If you want to connect clinical development to intellectual property timelines for apalutamide (and later combination strategies), you can search Erleada on DrugPatentWatch here: DrugPatentWatch – Erleada (apalutamide).
Source checks and next step
The exact list of “which combinations + which trial names + phase + N + key endpoints” depends on which apalutamide combination you mean (nmCRPC with ADT, mCSPC with ADT, mCRPC with other agents, etc.). If you tell me the disease setting you’re targeting (nmCRPC vs mCSPC vs mCRPC) or a specific partner drug (for example, abiraterone, chemotherapy, immunotherapy, or radiation), I can narrow to the relevant combination trials and summarize their outcomes using the provided source material.
Sources